HIVE-seq: a new way to map HIV-infected cells one cell at a time
Official title: HIVE-seq: A Novel Omics Technology to Profile Thousands of Single HIV-Positive Cells
Funded at Vivid Bioinnovations, Pbc · NIH-11256632 · Data updated 2026-11-12
A fast-track NIH SBIR project to develop HIVE-seq, a platform that identifies and characterizes HIV-infected cells in people living with HIV, including those who use opioids, without reactivating the virus.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vivid Bioinnovations, Pbc NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project start | August 19, 2026 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $307,074 |
| NIH project number | 1R44AI195215-01 |
| Project ID | NIH-11256632 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV, including those who use opioids, and who may contribute tissue or blood samples for research.
✕Less likely to help
If you do not have HIV or are not part of the targeted tissue sampling programs, you would not directly benefit from this project.
What this research studies
This project aims to build a new technology that profiles HIV-infected cells at the single-cell level across blood and tissues, preserving the natural state of the virus. It combines a full-length proviral sequencing method with single-cell omics to capture viral and host information from thousands of cells. In Phase I, the team will transfer methods to a commercial lab, validate protocols, and establish standard operating procedures for diverse tissues. Phase II plans to run an in-house service lab and start processing real patient samples, including from the Last Gift biorepository of PLWH who used opioids. The effort could accelerate the development of curative strategies by revealing detailed reservoirs of HIV in different tissues.
Why it matters
Potential benefit: If successful, this technology could advance understanding of HIV reservoirs and inform new approaches toward curing HIV.
How similar studies have gone: Previous academic methods exist, but HIVE-seq aims to combine full proviral sequences with host cell data in a non-reactivated state, representing an innovative approach.
Where this research is happening
-
Vivid Bioinnovations, Pbc
San Francisco, United States Active
Researchers
- Principal investigator: Schoepp, Nathan Garrett — Vivid Bioinnovations, Pbc
- Study coordinator: Schoepp, Nathan Garrett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.